Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study (Lancet Gastroenterology and Hepatology, 2022)

(untitled) - Liu, Z; Le, K; Zhou, X; Alexander, JL; Lin, S; Bewshea, C; Chanchlani, N; Nice, R; McDonald, TJ; Lamb, CA; Sebastian, S; Kok, K; et al.